4.7 Article

Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 66, 期 14, 页码 9972-9991

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.3c00880

关键词

-

向作者/读者索取更多资源

This study designed, synthesized, and identified a series of steroid analogs, among which YXG-158 (23-h) was a selective androgen receptor degrader with dual functions of AR degradation and CYP17A1 inhibition, showing promising therapeutic potential for enzalutamide-resistant prostate cancer.
The androgen/androgen receptor (AR) signaling pathwayplays animportant role in castration-resistant prostate cancer (CRPC). Bifunctionalagents that simultaneously degrade AR and inhibit androgen synthesisare expected to block the androgen/AR signaling pathway more thoroughly,demonstrating the promising therapeutic potential for CRPC, even enzalutamide-resistantCRPC. Herein, a series of steroid analogs were designed, synthesized,and identified as selective AR degraders, among which YXG-158 (23-h) was the most potent antitumor compound with dual functionsof AR degradation and CYP17A1 inhibition. In addition, 23-h abrogated the hERG inhibition and exhibited excellent PK profiles.In vivo, 23-h effectively inhibited the growth of hormone-sensitiveorgans in the Hershberger assay and exhibited robust antitumor efficacyboth in enzalutamide-sensitive (LNCaP/AR) and enzalutamide-resistant(C4-2b-ENZ) xenograft models. Thus, 23-h was chosen asa preclinical candidate for the treatment of enzalutamide-resistantprostate cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据